Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$7.50 USD
-0.40 (-5.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.50 USD
-0.40 (-5.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
by Kinjel Shah
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
by Zacks Equity Research
Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -1.19% and 1.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 21.92% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
by Zacks Equity Research
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
by Zacks Equity Research
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
by Zacks Equity Research
Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.
SAGE's Huntington's Disease Study Meets Primary Endpoint
by Zacks Equity Research
The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -10.43% and 28.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
by Zacks Equity Research
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
by Zacks Equity Research
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
by Zacks Equity Research
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.